维甲酸在诱导再分化治疗分化型甲状腺癌中的价值

叶智轶; 王辉; 吴靖川

叶智轶 , 王辉 , 吴靖川

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 4: (221-225)

引用本文:

Citation:

维甲酸在诱导再分化治疗分化型甲状腺癌中的价值

200092 上海, 上海交通大学医学院附属新华医院核医学科
中图分类号: R817.5

The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma

Department of Noclear Medicine, Xinhua Hospilal, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China
CLC number: R817.5

摘要: 分化型甲状腺癌约有30%肿瘤发生去分化,以致于术后¹³¹I治疗和甲状腺素替代治疗疗效差或无效。维甲酸作为维生素A的生物活性代谢产物,对于多种细胞的发生、增殖、分化起着重要的作用。多项研究发现,维甲酸诱导再分化治疗分化型甲状腺癌的潜力巨大。
- 分化型甲状腺癌 /
- 维甲酸 /
- 再分化
Abstract: About 30% of differentiated thyroid carcinoma(DTC) loses its ability of differentiation, which results in poor or no effect of the radioiodine therapy and the thyroid hormone replacement therapy after operation. Retinoic acids, the biologically active metabolite of vitamin A, is of central importance for growth, proliferation and differentiation of various cells. In this review, summarized the mechanism of the dedifferentiation among the DTC, the retinoic acids-induced redifferention and the clinical use of retinoic acids. It is demonstrated by many studies that retinoic acids-induced redifferentiaon has a large potential in the treatment of DTC.
- Differentiated thyroid carcinoma /
- Retinoic acids /
- Redifferentiation
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Grüning T,Tiepolts C,Zphel K,et al Retinoic acid for rediffer-entiation of thyroid cancer-does it hold its promise?.Eur J Endocrinol,2003,148(4):395-402.
[2]	Schmutzler C,Hoang-Vu C,Ruger B,et al. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses.Eur J Endocrinol,2004,150(4):547-556.
[3]	Elisei R,Pinchera A,Romei C,et al. Expression of thyrotropin receptor(TSH-R),thyroglobulin,thyroperoxidase,and calcitonin messenger ribonucleic acids in thyroid carcinomas:evidence of TSH-R gene transcript in medullary histotype.J Clin Endocrinol Metab,1994,78(4):867-871.
[4]	Kurebayashi J,Tanaka K,Otsuki T. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line,KTC-1.J Clin Endocrinol Metab,2000,85(8):2889-2896.
[5]	Schmutzler C,Khrle J. Innovative strategies for the treatment of thyroid cancer.Eur J Endocrinol,2000,143(1):15-24.
[6]	Ringel MD,Anderson J,Souza SL,et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.Mod Pathol,2001,14(4):289-296.
[7]	Russo D,Manole D,Arturi F,et al. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas.Thyroid,2001,11(1):37-39.
[8]	Dohan O,Baloch Z,Banrevi Z,et al. Predominant intracellular overexpression of the Na⁺/I^- symporter(NIS) in a large sampling of thyroid cancer cases.J Clin Endocrinol Metab,2001,86(6):2697-2700.
[9]	Tonacchera M,Viacava P,Agretti P,et al. Benignnonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.J Clin Endocrinol Metab,2002,87(1):352-357.
[10]	张一帆,李彪,赵龙,等. 维甲酸诱导甲状腺癌细胞摄碘的实验研究.中华核医学杂志,2005,25(2):90-93.
[11]	Klopper JP,Hays WR,Sharma V,et al. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinnet-reatment.Mol Cancer Ther,2004,3(8):1011-1020.
[12]	Elisei R,Vivaldi A,Agate L,et al. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor β messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.J Clin Endocrinol Metab,2005,90(4):2403-2411.
[13]	Coelho SM,Vaisman M,Carvalho DP,et al. Tumor redifferentiation effect of retinoic acid:a novel therapeutic approach for advanced thyroid cancer.Curr Pharma Des,2005,11(19):2525-2531.
[14]	Hoang-Vu C,Bull K,Schwarz I,et al. Regulation of CD97 protein in thyroid carcinoma.J Clin Endocrinol Metab,1999,84(3):1104-1109.
[15]	Simon D,Korber C,Krausch M,et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer:final results of a pilot study.Eur J Nucl Med Mol Imaging,2002,29(6):775-782.
[16]	张一帆,贾士铨,李彪,等. 维甲酸诱导分化治疗甲状腺癌的临床研究.中华内分泌代谢杂志,2006,4(22):101-110.
[17]	张雯杰,郑容,林琳,等. 维甲酸诱导分化在分化型甲状腺癌治疗中的初步应用.实用癌症杂志,2005,20(4):396-401.
[18]	Gr nwald F,Menzel C,Bender H,et al. Redifferentiation therapyinduced radioiodine uptake in thyroid cancer.J Nucl Med,1998,39(11):1903-1906.
[19]	Wang W,Larson SM,Fazzari M,et al. Prognostic value of[18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.J Clin Endocrinol Metab,2000,85(3):1107-1113.
[20]	Simon D,K hrle J,Reiners C. Redifferentation therapy with retinoids:therapeutic option for advanced follicular and papillary thyroid carcinoma.World J Surg,1998,22(6):569-574.
[21]	Haugen BR,Larson LL,Pugazhenthi U. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids.J Clin Endocrinol Metab,2004,89(1):272-280.

[1]	李艳玲 , 栾兆生 . 维甲酸在¹³¹I治疗分化型甲状腺癌中的应用. 国际放射医学核医学杂志, 2009, 33(4): 226-228. doi: 10.3760/cma.j.issn.1673-4114.2009.04.010
[2]	孟召伟 , 谭建 . 重组人促甲状腺激素和促再分化药物在分化型甲状腺癌中的应用. 国际放射医学核医学杂志, 2006, 30(6): 338-342.
[3]	张渊琪 , 赵德善 . 分化型甲状腺癌的治疗进展. 国际放射医学核医学杂志, 2017, 41(2): 126-131. doi: 10.3760/cma.j.issn.1673-4114.2017.02.009
[4]	李娇 , 韩娜 , 李凤岐 , 卢承慧 , 杨雪 , 林岩松 , 王叙馥 . 肺转移性分化型甲状腺癌术后¹³¹I治疗疗效及其影响因素的分析. 国际放射医学核医学杂志, 2022, 46(7): 405-411. doi: 10.3760/cma.j.cn121381-202203031-00204
[5]	孔维静 , 徐颖 . 综合干预措施下评估首次¹³¹I清甲治疗对分化型甲状腺癌患者唾液腺的慢性损伤. 国际放射医学核医学杂志, 2018, 42(1): 30-35. doi: 10.3760/cma.j.issn.1673-4114.2018.01.006
[6]	康玉国 . 分化型甲状腺癌¹⁸F-FDG PET显像的临床应用. 国际放射医学核医学杂志, 2000, 24(6): 264-267.
[7]	孙文杰 , 卢彦祺 , 牟兴宇 , 付巍 . 分化型甲状腺癌相关基因的研究进展. 国际放射医学核医学杂志, 2021, 45(5): 325-331. doi: 10.3760/cma.j.cn121381-202005009-00034
[8]	林岩松 . 分化型甲状腺癌¹³¹I治疗的争议与探索. 国际放射医学核医学杂志, 2022, 46(7): 389-391. doi: 10.3760/cma.j.cn121381-202206015-00196
[9]	温晓霞 , 赵德善 . PET/CT在分化型甲状腺癌复发和转移诊断中的应用进展. 国际放射医学核医学杂志, 2023, 47(3): 163-168. doi: 10.3760/cma.j.cn121381-202206008-00277
[10]	钞卫光 , 张晶 , 陆克义 . 分化型甲状腺癌腹盆部¹³¹I显像假阳性分析. 国际放射医学核医学杂志, 2017, 41(5): 370-373. doi: 10.3760/cma.j.issn.1673-4114.2017.05.012
[11]	南楠 , 朱小华 . 分化型甲状腺癌¹³¹I显像假阳性的原因分析. 国际放射医学核医学杂志, 2018, 42(1): 62-68. doi: 10.3760/cma.j.issn.1673-4114.2018.01.012